Curevo’s lead asset, amezosvatein, is a Phase 3-ready shingles vaccine with potential to increase vaccination rates by delivering improved tolerability versus approved products Seattle, WA – May 26, 2026 – Curevo Vaccine (Curevo), a clinical-stage biotechnology company dedicated to developing varicella zoster virus (VZV) vaccines with improved tolerability, today announced entry into a definitive…Read More
FLG and its partners deliver truly exceptional value. I have had the pleasure to work with three FLG partners—Mike Gennaro, John Finegan, and most recently Eric Hall—in both the SaaS and Life Sciences industries. Their ability to seamlessly integrate into operations and quickly develop a deep understanding of the company was particularly impressive. Each provided meaningful leadership and thoughtful guidance for the finance function, delivering both tactical and strategic value, including during times of company transition. They partnered with management to win, drove financing activities to successful conclusion, and were tireless in their dedication to company objectives.
Lisa Barbot, Current Principal Attorney, Barbot Law Read More
